QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PFE   39.99 (-0.57%)
PYPL   72.70 (-0.82%)
NFLX   323.52 (-1.26%)

Scholar Rock - SRRK Stock Forecast, Price & News

$7.36
-0.65 (-8.12%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.29
$8.03
50-Day Range
$7.36
$12.72
52-Week Range
$4.32
$15.32
Volume
255,923 shs
Average Volume
256,429 shs
Market Capitalization
$382.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.67

Scholar Rock MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
249.0% Upside
$25.67 Price Target
Short Interest
Bearish
6.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$455,061 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.38) to ($2.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

411th out of 1,002 stocks

Biological Products, Except Diagnostic Industry

72nd out of 166 stocks


SRRK stock logo

About Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
H.C. Wainwright Keeps Their Buy Rating on Scholar Rock Holding (SRRK)
Jay Backstrom is the new CEO at Scholar Rock
See More Headlines
Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Company Calendar

Last Earnings
3/07/2023
Today
3/28/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRRK
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.67
High Stock Price Forecast
$33.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+222.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-134,500,000.00
Pretax Margin
-405.21%

Debt

Sales & Book Value

Annual Sales
$33.19 million
Book Value
$5.04 per share

Miscellaneous

Free Float
50,919,000
Market Cap
$414.36 million
Optionable
Not Optionable
Beta
0.78

Key Executives

  • Jay T. Backstrom
    President, Chief Executive Officer & Director
  • Edward H. MylesEdward H. Myles
    Chief Financial Officer & Head-Business Operations
  • Mohammed Qatanani
    Senior Vice President & Head-Research
  • Jing L. Marantz
    Chief Medical Officer
  • Erin Moore
    Senior Vice President-Finance













SRRK Stock - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings
or view top-rated stocks.

What is Scholar Rock's stock price forecast for 2023?

5 brokers have issued 1-year price targets for Scholar Rock's stock. Their SRRK share price forecasts range from $19.00 to $33.00. On average, they anticipate the company's stock price to reach $25.67 in the next year. This suggests a possible upside of 222.0% from the stock's current price.
View analysts price targets for SRRK
or view top-rated stocks among Wall Street analysts.

How have SRRK shares performed in 2023?

Scholar Rock's stock was trading at $9.05 at the start of the year. Since then, SRRK shares have decreased by 11.9% and is now trading at $7.97.
View the best growth stocks for 2023 here
.

When is Scholar Rock's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our SRRK earnings forecast
.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) posted its quarterly earnings results on Tuesday, March, 7th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.11. During the same quarter in the previous year, the company posted ($0.97) earnings per share.

What ETFs hold Scholar Rock's stock?

ETFs with the largest weight of Scholar Rock (NASDAQ:SRRK) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB) and

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by a number of institutional and retail investors. Top institutional investors include Artal Group S.A. (17.38%), Price T Rowe Associates Inc. MD (13.62%), T. Rowe Price Investment Management Inc. (4.77%), Bank of America Corp DE (2.03%), Geode Capital Management LLC (0.70%) and Morgan Stanley (0.59%). Insiders that own company stock include Amir Nashat, Edward H Myles, Gregory John Carven, Jeffrey S Flier, Michael Gilman and Public Equities LP Invus.
View institutional ownership trends
.

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $7.97.

How much money does Scholar Rock make?

Scholar Rock (NASDAQ:SRRK) has a market capitalization of $414.36 million and generates $33.19 million in revenue each year. The company earns $-134,500,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

How many employees does Scholar Rock have?

The company employs 145 workers across the globe.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935.

This page (NASDAQ:SRRK) was last updated on 3/28/2023 by MarketBeat.com Staff